AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$RVTY

Revvity earnings beat by $0.07, revenue topped estimates

Revvity (RVTY) reported Q3 EPS of $1.37, beating estimates by $0.07, with revenue at $729M, exceeding expectations of $694.72M. The company guided FY 2026 EPS to $5.40-$5.45 and revenue to $2.86B, both slightly above consensus. RVTY's stock is up 32.70% in 3 months and 65.34% in 12 months.

Original reporting
investing.com
Published Nov 3, 2026, 11:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The earnings beat and raised FY guidance improve Revvity's valuation outlook, likely prompting buying pressure.

02

Market read

First‑report earnings beat with guidance lift for a mid‑cap U.S. stock; actionable for short‑term traders.

03

What to watch

Potential headwinds from supply‑chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Revvity (NYSE: RVTY) is a provider of life‑science instrumentation and consumables.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Revvity reported Q3 EPS of $1.37 beating estimates by $0.07 and raised FY 2026 guidance, a fresh earnings disclosure.

Expected impact

likely upward pressure as investors price in the earnings beat and higher FY guidance

Evidence & confidence

The beat and guidance lift expectations for future earnings, prompting buying interest.

Market effects

Sector

Positive for the life-sciences equipment sector as Revvity's beat may lift peers.

Regional

U.S. market may see modest gains in related biotech and diagnostics stocks.

Global

Limited to investors tracking U.S. mid‑cap earnings; no broad global impact.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑cover pull‑back.

Key entities

  • Company
    Revvity

    Life‑science instrumentation and consumables provider.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

4 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min